Saturday 17 October 2026
Export SXTC’s income statement to Excel — free account
China SXT Pharmaceuticals, Inc.
SXTC Healthcare Drug Manufacturers Specialty & Generic
China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.
0.07
0.00
0.00%
Follow SXTC
| Older periods | Sep '24 | Mar '25 | Sep '25 | Mar '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
1.29 | 3.30 | 4.01 | 7.17 | |
Current Ratio |
1.40 | 3.54 | 4.37 | 7.94 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
7.14% | 3.73% | 4.00% | 2.87% | |
Debt/Equity |
0.15 | 0.05 | 0.05 | 0.03 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.59 | 0.77 | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(1.32) | (2.28) | (1.75) | (4.02) | |
Working Capital |
6.32 | 15.28 | 20.08 | 30.16 | |
Capital Expenditures |
0.04 | 0.06 | — | 0.00 | |
Net Current Asset Value |
6.03 | 15.07 | 19.92 | 29.46 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
3.87 | 1.53 | 2.01 | 2.16 | |
Average Payables |
1.61 | 1.27 | 0.92 | 0.89 | |
Average Inventory |
0.75 | 0.68 | 0.62 | 0.79 | |
Average Assets |
26.59 | 25.61 | 20.47 | 28.94 | |
Average Common Equity |
14.96 | 15.07 | 12.66 | 21.82 |
Columns are period end dates